0001640334-25-000711 Sample Contracts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 28th, 2025 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 24, 2025, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Pre-Funded Common Stock Purchase Warrant • April 28th, 2025 • Lexaria Bioscience Corp. • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Placement Agent Agreement • April 28th, 2025 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 24, 2030 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain engagement letter, dated as of February 24, 2025, as amended, by and between the Company and H.C. Wainwright & Co., LLC.
STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Richard Christopher, Chief Executive Officer Dear Mr. Christopher:Underwriting Agreement • April 28th, 2025 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”), effective as of as of the date hereof, constitutes the agreement between Lexaria Bioscience Corp. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive underwriter, agent or advisor in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement; provided, however, that the Company’s existing Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC shall be excluded from this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to t
STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Richard Christopher, Chief Executive Officer Dear Mr. Christopher:Engagement Agreement • April 28th, 2025 • Lexaria Bioscience Corp. • Pharmaceutical preparations
Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of February 24, 2025, by and between Lexaria Bioscience Corp. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Defined terms used herein but not defined herein shall have the meanings given to such terms in the Engagement Agreement.